Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 420

1.

Rejuvenation of mucosal immunosenescence by adipose tissue-derived mesenchymal stem cells.

Tsuruhara A, Aso K, Tokuhara D, Ohori J, Kawabata M, Kurono Y, McGhee JR, Fujihashi K.

Int Immunol. 2017 Jan 1;29(1):5-10. doi: 10.1093/intimm/dxx001. Review.

2.

Adipose-Derived Mesenchymal Stem Cells Restore Impaired Mucosal Immune Responses in Aged Mice.

Aso K, Tsuruhara A, Takagaki K, Oki K, Ota M, Nose Y, Tanemura H, Urushihata N, Sasanuma J, Sano M, Hirano A, Aso R, McGhee JR, Fujihashi K.

PLoS One. 2016 Feb 3;11(2):e0148185. doi: 10.1371/journal.pone.0148185. eCollection 2016.

3.

A molecular mucosal adjuvant to enhance immunity against pneumococcal infection in the elderly.

Fukuyama Y, Ikeda Y, Ohori J, Sugita G, Aso K, Fujihashi K, Briles DE, McGhee JR, Fujihashi K.

Immune Netw. 2015 Feb;15(1):9-15. doi: 10.4110/in.2015.15.1.9. Epub 2015 Feb 17. Review.

4.

Potential roles of CCR5(+) CCR6(+) dendritic cells induced by nasal ovalbumin plus Flt3 ligand expressing adenovirus for mucosal IgA responses.

Fukuyama Y, Tokuhara D, Sekine S, Aso K, Kataoka K, Davydova J, Yamamoto M, Gilbert RS, Tokuhara Y, Fujihashi K, Kunisawa J, Yuki Y, Kiyono H, McGhee JR, Fujihashi K.

PLoS One. 2013;8(4):e60453. doi: 10.1371/journal.pone.0060453. Epub 2013 Apr 2.

5.

Inside the mucosal immune system.

McGhee JR, Fujihashi K.

PLoS Biol. 2012;10(9):e1001397. doi: 10.1371/journal.pbio.1001397. Epub 2012 Sep 25.

6.

Novel vaccine development strategies for inducing mucosal immunity.

Fujkuyama Y, Tokuhara D, Kataoka K, Gilbert RS, McGhee JR, Yuki Y, Kiyono H, Fujihashi K.

Expert Rev Vaccines. 2012 Mar;11(3):367-79. doi: 10.1586/erv.11.196. Review.

7.

A mucosal gateway for vaccines.

McGhee JR.

Nat Biotechnol. 2011 Feb;29(2):136-8. doi: 10.1038/nbt.1766. No abstract available.

PMID:
21301439
8.

A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity.

Fukuiwa T, Sekine S, Kobayashi R, Suzuki H, Kataoka K, Gilbert RS, Kurono Y, Boyaka PN, Krieg AM, McGhee JR, Fujihashi K.

Vaccine. 2008 Sep 2;26(37):4849-59. doi: 10.1016/j.vaccine.2008.06.091. Epub 2008 Jul 14.

9.

Ovalbumin-protein sigma 1 M-cell targeting facilitates oral tolerance with reduction of antigen-specific CD4+ T cells.

Suzuki H, Sekine S, Kataoka K, Pascual DW, Maddaloni M, Kobayashi R, Fujihashi K, Kozono H, McGhee JR, Fujihashi K.

Gastroenterology. 2008 Sep;135(3):917-25. doi: 10.1053/j.gastro.2008.05.037. Epub 2008 May 15.

10.

A novel adenovirus expressing Flt3 ligand enhances mucosal immunity by inducing mature nasopharyngeal-associated lymphoreticular tissue dendritic cell migration.

Sekine S, Kataoka K, Fukuyama Y, Adachi Y, Davydova J, Yamamoto M, Kobayashi R, Fujihashi K, Suzuki H, Curiel DT, Shizukuishi S, McGhee JR, Fujihashi K.

J Immunol. 2008 Jun 15;180(12):8126-34.

11.

Measurement of TGF-beta in biological fluids.

Hale-Donze H, Wahl SM, Jackson RJ, McGhee JR.

Curr Protoc Immunol. 2001 May;Chapter 6:Unit 6.11. doi: 10.1002/0471142735.im0611s41.

PMID:
18432803
12.

Low-dose tolerance is mediated by the microfold cell ligand, reovirus protein sigma1.

Rynda A, Maddaloni M, Mierzejewska D, Ochoa-Repáraz J, Maslanka T, Crist K, Riccardi C, Barszczewska B, Fujihashi K, McGhee JR, Pascual DW.

J Immunol. 2008 Apr 15;180(8):5187-200.

13.

Nasal cholera toxin elicits IL-5 and IL-5 receptor alpha-chain expressing B-1a B cells for innate mucosal IgA antibody responses.

Kataoka K, Fujihashi K, Sekine S, Fukuiwa T, Kobayashi R, Suzuki H, Nagata H, Takatsu K, Shizukuishi S, McGhee JR, Fujihashi K.

J Immunol. 2007 May 15;178(10):6058-65.

14.

Th1 and Th2 cells are required for both eosinophil- and neutrophil-associated airway inflammatory responses in mice.

Fischer R, Tomé D, McGhee JR, Boyaka PN.

Biochem Biophys Res Commun. 2007 May 25;357(1):44-9. Epub 2007 Mar 19.

15.

Gut lymphocyte migration: we are halfway 'home'.

McGhee JR, Kunisawa J, Kiyono H.

Trends Immunol. 2007 Apr;28(4):150-3. Epub 2007 Feb 9. Review.

PMID:
17293162
16.

Mucosal vaccine targeting improves onset of mucosal and systemic immunity to botulinum neurotoxin A.

Maddaloni M, Staats HF, Mierzejewska D, Hoyt T, Robinson A, Callis G, Kozaki S, Kiyono H, McGhee JR, Fujihashi K, Pascual DW.

J Immunol. 2006 Oct 15;177(8):5524-32.

17.

A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking.

Hagiwara Y, Kawamura YI, Kataoka K, Rahima B, Jackson RJ, Komase K, Dohi T, Boyaka PN, Takeda Y, Kiyono H, McGhee JR, Fujihashi K.

J Immunol. 2006 Sep 1;177(5):3045-54.

18.

HIV infection: first battle decides the war.

Hel Z, McGhee JR, Mestecky J.

Trends Immunol. 2006 Jun;27(6):274-81. Epub 2006 May 6.

PMID:
16679064
19.

Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens.

Duverger A, Jackson RJ, van Ginkel FW, Fischer R, Tafaro A, Leppla SH, Fujihashi K, Kiyono H, McGhee JR, Boyaka PN.

J Immunol. 2006 Feb 1;176(3):1776-83.

20.

Oral and nasal sensitization promote distinct immune responses and lung reactivity in a mouse model of peanut allergy.

Fischer R, McGhee JR, Vu HL, Atkinson TP, Jackson RJ, Tomé D, Boyaka PN.

Am J Pathol. 2005 Dec;167(6):1621-30.

21.

Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract.

van Ginkel FW, Jackson RJ, Yoshino N, Hagiwara Y, Metzger DJ, Connell TD, Vu HL, Martin M, Fujihashi K, McGhee JR.

Infect Immun. 2005 Oct;73(10):6892-902.

22.

Peyer's patch germinal centers: the elusive switch site for IgA.

McGhee JR.

J Immunol. 2005 Aug 1;175(3):1361-2. No abstract available.

23.

Novel approaches for the induction of T helper 1 (Th1)- or Th2-type mucosal and parenteral immune responses.

Marinaro M, Boyaka PN, Kiyono H, McGhee JR.

Expert Opin Investig Drugs. 1998 Oct;7(10):1657-66.

PMID:
15991907
24.

The world of TH1/TH2 subsets: first proof.

McGhee JR.

J Immunol. 2005 Jul 1;175(1):3-4. No abstract available.

25.

A novel neurotoxoid vaccine prevents mucosal botulism.

Kobayashi R, Kohda T, Kataoka K, Ihara H, Kozaki S, Pascual DW, Staats HF, Kiyono H, McGhee JR, Fujihashi K.

J Immunol. 2005 Feb 15;174(4):2190-5.

26.

Mucosal immunity and tolerance in the elderly.

Fujihashi K, McGhee JR.

Mech Ageing Dev. 2004 Dec;125(12):889-98. Review.

PMID:
15563935
27.

A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates.

Yoshino N, Lü FX, Fujihashi K, Hagiwara Y, Kataoka K, Lu D, Hirst L, Honda M, van Ginkel FW, Takeda Y, Miller CJ, Kiyono H, McGhee JR.

J Immunol. 2004 Dec 1;173(11):6850-7.

28.

CD4+CD45RBHi interleukin-4 defective T cells elicit antral gastritis and duodenitis.

Dohi T, Fujihashi K, Koga T, Etani Y, Yoshino N, Kawamura YI, McGhee JR.

Am J Pathol. 2004 Oct;165(4):1257-68.

29.

Granulocyte chemotactic protein-2 mediates adaptive immunity in part through IL-8Rbeta interactions.

Singh UP, Singh S, Boyaka PN, McGhee JR, Lillard JW Jr.

J Leukoc Biol. 2004 Dec;76(6):1240-7. Epub 2004 Sep 8.

PMID:
15356099
30.

Role of gut-associated lymphoreticular tissues in antigen-specific intestinal IgA immunity.

Yamamoto M, Kweon MN, Rennert PD, Hiroi T, Fujihashi K, McGhee JR, Kiyono H.

J Immunol. 2004 Jul 15;173(2):762-9.

31.

Pathological role of large intestinal IL-12p40 for the induction of Th2-type allergic diarrhea.

Hino A, Kweon MN, Fujihashi K, McGhee JR, Kiyono H.

Am J Pathol. 2004 Apr;164(4):1327-35.

32.

Nasal Flt3 ligand cDNA elicits CD11c+CD8+ dendritic cells for enhanced mucosal immunity.

Kataoka K, McGhee JR, Kobayashi R, Fujihashi K, Shizukuishi S, Fujihashi K.

J Immunol. 2004 Mar 15;172(6):3612-9.

33.

Pneumococcal carriage results in ganglioside-mediated olfactory tissue infection.

van Ginkel FW, McGhee JR, Watt JM, Campos-Torres A, Parish LA, Briles DE.

Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14363-7. Epub 2003 Nov 10. Erratum in: Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6834.

34.

IFN-gamma-inducible chemokines enhance adaptive immunity and colitis.

Singh UP, Singh S, Iqbal N, Weaver CT, McGhee JR, Lillard JW Jr.

J Interferon Cytokine Res. 2003 Oct;23(10):591-600.

PMID:
14585199
35.

Cholera toxin activates dendritic cells through dependence on GM1-ganglioside which is mediated by NF-kappaB translocation.

Kawamura YI, Kawashima R, Shirai Y, Kato R, Hamabata T, Yamamoto M, Furukawa K, Fujihashi K, McGhee JR, Hayashi H, Dohi T.

Eur J Immunol. 2003 Nov;33(11):3205-12.

36.

Therapeutic manipulation of the immune system: enhancement of innate and adaptive mucosal immunity.

Boyaka PN, Tafaro A, Fischer R, Fujihashi K, Jirillo E, McGhee JR.

Curr Pharm Des. 2003;9(24):1965-72. Review.

PMID:
12871182
37.

Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.

Boyaka PN, Tafaro A, Fischer R, Leppla SH, Fujihashi K, McGhee JR.

J Immunol. 2003 Jun 1;170(11):5636-43.

38.

T helper type-2 cells induce ileal villus atrophy, goblet cell metaplasia, and wasting disease in T cell-deficient mice.

Dohi T, Fujihashi K, Koga T, Shirai Y, Kawamura YI, Ejima C, Kato R, Saitoh K, McGhee JR.

Gastroenterology. 2003 Mar;124(3):672-82.

PMID:
12612906
39.

Lack of oral tolerance in aging is due to sequential loss of Peyer's patch cell interactions.

Kato H, Fujihashi K, Kato R, Dohi T, Fujihashi K, Hagiwara Y, Kataoka K, Kobayashi R, McGhee JR.

Int Immunol. 2003 Feb;15(2):145-58.

PMID:
12578844
40.

Protective mucosal immunity in aging is associated with functional CD4+ T cells in nasopharyngeal-associated lymphoreticular tissue.

Hagiwara Y, McGhee JR, Fujihashi K, Kobayashi R, Yoshino N, Kataoka K, Etani Y, Kweon MN, Tamura S, Kurata T, Takeda Y, Kiyono H, Fujihashi K.

J Immunol. 2003 Feb 15;170(4):1754-62.

41.

Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit.

Boyaka PN, Ohmura M, Fujihashi K, Koga T, Yamamoto M, Kweon MN, Takeda Y, Jackson RJ, Kiyono H, Yuki Y, McGhee JR.

J Immunol. 2003 Jan 1;170(1):454-62.

42.

A nontoxic chimeric enterotoxin adjuvant induces protective immunity in both mucosal and systemic compartments with reduced IgE antibodies.

Kweon MN, Yamamoto M, Watanabe F, Tamura S, Van Ginkel FW, Miyauchi A, Takagi H, Takeda Y, Hamabata T, Fujihashi K, McGhee JR, Kiyono H.

J Infect Dis. 2002 Nov 1;186(9):1261-9. Epub 2002 Oct 3.

PMID:
12402195
43.

MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity.

Lillard JW Jr, Singh UP, Boyaka PN, Singh S, Taub DD, McGhee JR.

Blood. 2003 Feb 1;101(3):807-14. Epub 2002 Sep 12.

PMID:
12393512
44.

Characterization of protective immune responses induced by nasal influenza vaccine containing mutant cholera toxin as a safe adjuvant (CT112K).

Watanabe I, Hagiwara Y, Kadowaki SE, Yoshikawa T, Komase K, Aizawa C, Kiyono H, Takeda Y, McGhee JR, Chiba J, Sata T, Kurata T, Tamura S.

Vaccine. 2002 Oct 4;20(29-30):3443-55.

PMID:
12297389
45.

A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants.

Fujihashi K, Koga T, van Ginkel FW, Hagiwara Y, McGhee JR.

Vaccine. 2002 Jun 7;20(19-20):2431-8. Review.

PMID:
12057597
46.

Salmonella-mediated mucosal cell-mediated immunity.

Lillard JW Jr, Boyaka PN, Singh S, McGhee JR.

Cell Mol Biol (Noisy-le-grand). 2001 Nov;47(7):1115-20.

PMID:
11838959
47.

Highly purified mutant E112K of cholera toxin elicits protective lung mucosal immunity to diphtheria toxin.

Ohmura M, Yamamoto M, Kiyono H, Fujihashi K, Takeda Y, McGhee JR.

Vaccine. 2001 Dec 12;20(5-6):756-62.

PMID:
11738739
48.

A revisit of mucosal IgA immunity and oral tolerance.

Fujihashi K, Kato H, van Ginkel FW, Koga T, Boyaka PN, Jackson RJ, Kato R, Hagiwara Y, Etani Y, Goma I, Fujihashi K, Kiyono H, McGhee JR.

Acta Odontol Scand. 2001 Oct;59(5):301-8. Review.

PMID:
11680650
49.

Resistance of T-cell receptor delta-chain-deficient mice to experimental Candida albicans vaginitis.

Wormley FL Jr, Steele C, Wozniak K, Fujihashi K, McGhee JR, Fidel PL Jr.

Infect Immun. 2001 Nov;69(11):7162-4.

Supplemental Content

Loading ...
Support Center